Conference Calendar

November 5-8 - American Academy of Implant Dentistry

November 7-9 - American Association of Hip and Knee Surgeons

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art

RSS



app icon

iPhone

app store icon

Kindle



Orthopedic and Dental Industry News Complete Archive »

Interpore Cross

Orthopedic News Roundup 06-Oct-05 BY HUYEN NGUYEN, OCTOBER 6, 2005

While Medtronic was the big winner this week, Wright Medical ("WMGI") captured more headlines with two important news items that have negatively impacted their stock price. On Wednesday, WMGI's stock price suffered a huge loss with 20% decline intraday due... more

Biomet Revises 4Q:05 Earnings Guidance Downward BY JOHN CHOPACK, JUNE 21, 2005

Biomet announced last evening that it was reducing its 4Q:05 earnings guidance as a consequence of hitting the low end of its previous range for 4Q:05 revenues. The Company stated that revenues totaled $503 million for the 4Q:05 which is... more

Biomet (BMET:NASDAQ) Reports 3Q:05 Results; Knee Revenues Increase 31% BY JOHN CHOPACK, MARCH 28, 2005

Biomet reported an 18% increase in net sales which totaled $482 million during the 3Q:05. The company also reported earnings, excluding any one-time costs associated with its recent Interpore Cross or Biomet Merck acquisitions, totaled $0.40 per diluted share which... more

Orthopedics Growing 2.5x Faster than U.S. GDP BY EDITOR, NOVEMBER 3, 2003

For the third quarter, with three more companies yet to report, public orthopedic companies have reported that their sales grew 17.5% on a year-over-year basis. To put that into perspective, U.S. GDP grew at a 7.2% annual rate in the... more

Interpore Cross posts 266% earnings increase on 25% sales increase BY EDITOR, JULY 21, 2003

$1.1 million in royalty revenue from AcroMed, combined with 25% increase in spinal implant revenues and the glimmer of a turnaround at AOM (MIS) set the stage for a sharp earnings increase for the second quarter. Royalties are now the... more

It's going to be a great Quarter, Year and Decade BY EDITOR, JULY 14, 2003

Despite being asked by the Merrill analyst to comment on the prospects for the Next Gen product (manufactured by Zimmer... oops, she meant Next Generation), Biomet's CEO, Dane Miller, was his usual wry self as he announced that overall sales... more

Rumors of the death of Product Mix price increases greatly exaggerated BY EDITOR, APRIL 21, 2003

Exhibit A: Stryker Exhibit B: Interpore Cross Not to pick on Merrill Lynch... but, and we quote, "Product mix benefit may slow a tad... we suspect this mix benefit has been largely realized." Cementless hip stems, metal on metal components... more

First Quarter's Recon Revenue Growth Rate - so far 20-24% BY EDITOR, APRIL 21, 2003

As the following table illustrates, revenue growth rates for the first week of earnings season are ranging from 15% for Interpore Cross to 32% for Synvisc' (sold by Genzyme Biosurgery). The DePuy and Stryker (#1 and #2 orthopedic market share,... more


Complete Archive